Poseida Therapeutics

Edit info

Founded: 2015

Location: San Diego, CA

Employee range: 200 - 500

Clinical stage: Clin1

Therapy area: Multiple myeloma

Drug types: ONC, HEM, GEN, RAR

Lead product: P-BCMA-ALL01 (partner: Roche)

Funding: $80.5M stock Aug 2022; $258M IPO Jul 2020; $110M D Jun 2020; $142M Apr 2019; $30.5M B Apr 2018

Investors: Novartis

poseida.com

linkedin.com

job board

Business:

Genome Editing Technologies

Drug notes:

P-MUC1C-ALL01 Clin1 solid tumors; P-CD19CD20-ALLO1 Clin1 B-cell malignancies (partner: Roche); 4 programs Clin0 multiple cancers; P-OTC-101 Clin0 OTC deficiency; P-FVIII-101 Clin0 hemophilia A; P-PAH-101 Clin0 phenylketonuria

About:

Poseida Therapeutics is developing next-generation gene engineering technologies. Using their proprietary genetic engineering platform combining the piggyBac DNA Modification System, Cas-CLOVER Gene Editing System and Nanparticle/AAV Delivery Technology, Poseida is developing single treatment cures that efficiently deliver genetic cargo into cells. Poseida’s gene engineering technologies represent the next wave of innovation and brings hope to patients with cancer and genetic disease. Poseida is advancing product candidates including CAR-T therapies to harness the power of a patient’s own immune system.